Recombinant epidermal growth factor(Bharat Biotech International Ltd.)(Recombinant epidermal growth factor(Bharat Biotech International Ltd.))

概要

基本信息

药物类型

生长因子

别名

Recombinant epidermal growth factor、Recombinant human epidermal growth factor、hrecEGF

+ [5]

靶点

EGFR

作用机制

EGFR激动剂(表皮生长因子受体erbB1激动剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

烧伤糖尿病足

非在研适应症-

原研机构

Bharat Biotech International Ltd.

在研机构

Bharat Biotech International Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

印度 (2005-01-01),

烧伤糖尿病足

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Recombinant epidermal growth factor(Bharat Biotech International Ltd.) 相关的临床试验

CTRI/2024/05/067239 / Not yet recruiting临床3期IIT

Effect of topical recombinant human epidermal growth factor on chronic diabetic ulcer compared with conventional saline dressing - Randomized controlled trial - NIL

开始日期2024-05-20

申办/合作机构-

NCT04431687 / Completed临床1期

A Randomized, Open-label, 2-Part, Multiple-dose, Two-way Crossover Clinical Trial to Evaluate Drug-drug Interactions and Safety Between CKD-501, D759, and D150 in Healthy Adults

A Clinical trial to investigate the pharmacokinetic drug interaction and safety of CKD-501, D759 and D150

开始日期2020-06-15

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

NCT04334213 / Completed临床1期

A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interactions and Safety After Oral Administration of D745, D150 and CKD-501 in Healthy Adults

A Clinical trial to investigate the pharmacokinetic drug interaction and safety of CKD-501, D745 and D150

开始日期2020-05-07

申办/合作机构

Chong Kun Dang Pharmaceutical Corp.

100 项与 Recombinant epidermal growth factor(Bharat Biotech International Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant epidermal growth factor(Bharat Biotech International Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant epidermal growth factor(Bharat Biotech International Ltd.) 相关的专利（医药）

登录后查看更多信息

187

项与 Recombinant epidermal growth factor(Bharat Biotech International Ltd.) 相关的文献（医药）

2024-10-01·International Journal of Biological Macromolecules

Concanavalin-conjugated zinc-metal-organic framework drug for pH-controlled and targeted therapy of wound bacterial infection

Article

作者: Zhang, Chong ; Hu, Junli ; Gao, Yuwei ; Li, Na ; Xin, Gaoli ; Wang, Yexing ; He, Xiuxia ; Wang, Zuobin

Wounds are prone to infection which may be fatal to the life of the patient. The use of antibiotics is essential for managing bacterial infections in wounds, but the long-term use of high doses of antibiotics may lead to bacterial drug resistance and even to creation of superbacteria. Therefore, the development of targeted antimicrobial treatment strategies and the reduction in antibiotic usage are of utmost urgency. In this study, a multifunctional nanodrug delivery system (Cef-rhEGF@ZIF-8@ConA) for the treatment of bacteriostatic infection was synthesized through self-assembly of Zn²⁺, cefradine (Cef) and recombinant human epidermal growth factor (rhEGF), then conjugated with concanavalin (ConA), which undergoes pH-responsive degradation to release the drugs. First, ConA can specifically combine with bacteria and inhibit the rapid release of Zn²⁺ ions, thus achieving a long-acting antibacterial effect. Cef exerts its antibacterial effect by inhibiting the synthesis of bacterial membrane proteins. Finally, Zn²⁺ ions released from the Zn-metal-organic framework (MOF) demonstrate bacteriostatic properties by enhancing the permeability of the bacterial cell membrane. Furthermore, rhEGF upregulates angiogenesis-associated genes, thereby promoting angiogenesis, re-epithelialization and wound healing processes. The results showed that Cef-rhEGF@ZIF-8@ConA has good biocompatibility, with antibacterial efficacy against Staphylococcus aureus and Escherichia coli of 99.61 % and 99.75 %, respectively. These nanomaterials can inhibit the release of inflammatory cytokines and promote the release of anti-inflammatory cytokines, while also stimulating the proliferation of fibroblasts to facilitate wound healing. Taken together, the Cef-rhEGF@ZIF-8@ConA nanosystem is an excellent candidate in clinical therapeutics for bacteriostatic infection and wound healing.

2024-08-01·Drug Development Research

Recombinant human epidermal growth factor‐loaded liposomes and transferosomes for dermal delivery: Development, characterization, and cytotoxicity evaluation

Article

作者: Doustvaghe, Yasaman Kiani ; Amirkhani, Mohammad Amir ; Vatanpour, Hossein ; Sisakht, Mahsa Mollapour ; Haeri, Azadeh

AbstractRecombinant human epidermal growth factor (rhEGF) is widely utilized as an antiaging compound in wound‐healing therapies and cosmetic purposes. However, topical administration of rhEGF has limited treatment outcomes because of its poor percutaneous penetration and rapid proteinase degradation. To overcome these obstacles, this study aims to develop and characterize rhEGF‐containing conventional liposomes (rhEGF‐CLs) and transferosomes (rhEGF‐TFs) as efficient dermal carriers. Physicochemical characterization such as particle size, zeta potential (ZP), morphology, encapsulation efficiency (EE%), and release properties of nanocarriers as well as in vitro cytotoxicity in human dermal fibroblast (HDF) and human embryonic kidney (HEK293) cell lines were investigated. rhEGF‐TFs at the rhEGF concentration ranging from 0.05 to 1.0 μg/mL were chosen as the optimum formulation due to the desired release profile, acceptable EE%, optimal cell proliferation, and minimal cytotoxicity compared to the control and free rhEGF. However, higher concentrations caused a decrease in cell viability. The ratio 20:80 of Tween 80 to lipid was optimal for rhEGF‐TFs‐2, which had an average diameter of 233.23 ± 2.64 nm, polydispersity index of 0.33 ± 0.05, ZP of −15.46 ± 0.29 mV, and EE% of 60.50 ± 1.91. The formulations remained stable at 5°C for at least 1 month. TEM and SEM microscopy revealed that rhEGF‐TFs‐2 had a regular shape and unilamellar structure. In vitro drug release studies confirmed the superiority of rhEGF‐TFs‐2 in terms of optimal cumulative release of rhEGF approximately 82% within 24 h. Franz diffusion cell study showed higher rhEGF‐TFs‐2 skin permeation compared to free rhEGF solution. Taken together, we concluded that rhEGF‐TFs can be used as a promising formulation for wound healing and skin regeneration products.

2024-08-01·International Journal of Biological Macromolecules

Electrospinning/3D printing drug-loaded antibacterial polycaprolactone nanofiber/sodium alginate-gelatin hydrogel bilayer scaffold for skin wound repair

Article

作者: Liu, Suihong ; Wang, Yahao ; Song, Yongteng ; Hu, Qingxi ; Zhang, Haiguang ; Chen, Jianghan ; Yao, Guotai

Skin injuries and defects, as a common clinical issue, still cannot be perfectly repaired at present, particularly large-scale and infected skin defects. Therefore, in this work, a drug-loaded bilayer skin scaffold was developed for repairing full-thickness skin defects. Briefly, amoxicillin (AMX) was loaded on polycaprolactone (PCL) nanofiber via electrospinning to form the antibacterial nanofiber membrane (PCL-AMX) as the outer layer of scaffold to mimic epidermis. To maintain wound wettability and promote wound healing, external human epidermal growth factor (rhEGF) was loaded in sodium alginate-gelatin to form the hydrogel structure (SG-rhEGF) via 3D printing as inner layer of scaffold to mimic dermis. AMX and rhEGF were successfully loaded into the scaffold. The scaffold exhibited excellent physicochemical properties, with elongation at break and tensile modulus were 102.09 ± 6.74% and 206.83 ± 32.10 kPa, respectively; the outer layer was hydrophobic (WCA was 112.09 ± 4.67°), while the inner layer was hydrophilic (WCA was 48.87 ± 5.52°). Meanwhile, the scaffold showed excellent drug release and antibacterial characteristics. In vitro and in vivo studies indicated that the fabricated scaffold could enhance cell adhesion and proliferation, and promote skin wound healing, with favorable biocompatibility and great potential for skin regeneration and clinical application.

100 项与 Recombinant epidermal growth factor(Bharat Biotech International Ltd.) 相关的药物交易

登录后查看更多信息